
|Videos|June 4, 2017
Dr. Apolo on Updated JAVELIN Results of Avelumab in Urothelial Carcinoma
Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.
Advertisement
Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.
<<<
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Hematologists Highlight Top Data From ASCO 2026
3
Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS
4
INDEPENDENCE, Type II JAK Inhibitor Data Highlight Key MPN and AML Data Arriving at EHA 2026
5






































































